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Objectives The aim of this study was to determine renal outcomes after left ventricular assist device (LVAD) implantation.
Background Renal dysfunction before LVAD placement is frequent, and it is unclear whether it is due to primary renal dis-
ease or to poor perfusion.
Methods A retrospective single-center analysis was conducted in 83 consecutive patients implanted with HeartMate II
continuous-flow LVADs (Thoratec Corp., Pleasanton, California). Calculated glomerular filtration rate (GFR) was as-
sessed on admission and 1, 3, and 6 months after implantation. To define predictors for improvement in GFR, clinical
variables were examined in patients with decreased renal function (GFR 60 ml/min/1.73 m2) before LVAD, surviv-
ing and dialysis-free at 1 month (n  44).
Results GFR significantly increased from admission (53.2  21.4 ml/min/1.73 m2) to 1 month after LVAD implantation
(87.4  27.9 ml/min/1.73 m2) (p  0.0001). Subsequently, at 3 and 6 months, GFR remained significantly
(p  0.0001) above pre-LVAD values. Of the 51 patients with GFRs 60 ml/min/1.73 m2 before LVAD surviving
at 1 month, 34 (67%) improved to GFRs 60 ml/min/1.73 m2. Univariate pre-operative predictors for improve-
ment in renal function at 1 month included younger age (p  0.049), GFR improvement with optimal medical
therapy (p  0.001), intra-aortic balloon pump use (p  0.004), kidney length above 10 cm (p  0.023), no
treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (p  0.029), higher
bilirubin (p  0.002), higher Lietz-Miller score (p  0.019), and atrial fibrillation (p  0.007). Multivariate analy-
sis indicated pre-operative improved GFR (slope  0.5 U per unit improved; 95% confidence interval: 0.2 to 0.8;
p  0.003), atrial fibrillation (slope  27; 95% confidence interval: 8 to 46; p  0.006), and intra-aortic balloon
pump use (slope  14; 95% confidence interval: 2 to 26; p  0.02) as independent predictors.
Conclusions In most patients with end-stage heart failure considered for LVAD implantation, renal dysfunction is reversible
and likely related to poor renal perfusion. (J Am Coll Cardiol 2012;59:26–36) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.038Renal dysfunction (RD) is frequent in patients with chronic
congestive heart failure (1). Moderate to severe RD, defined
by a glomerular filtration rate (GFR) 60 ml/min/1.73 m2,
has been documented in up to 45% of patients with
ambulatory heart failure (2) and in 64% of patients hospi-
talized for decompensated heart failure (3). Compared with
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accepted September 20, 2011.patients with heart failure without RD, these patients
experience higher morbidity and mortality (4). The optimal
management of these patients is unclear, because they have
been generally excluded from the major trials of congestive
heart failure (5–7).
The question of renal function is especially important in
those patients with end-stage heart failure who are consid-
ered for advanced therapy such as left ventricular assist
device (LVAD) placement or heart transplantation. Cardiac
transplant recipients have an increased risk for renal impair-
ment after transplantation (8), which is higher than for
other forms of cardiac surgery (9). Subsequently, there is
continuous risk related to calcineurin-inhibitor immuno-
suppressive medication, which also results in a progressive
decline in renal function. Indeed, the preferred strategy at
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December 27, 2011/January 3, 2012:26–36 Renal Function After LVAD Implantationmany cardiac transplantation centers for the treatment of
heart transplantation candidates with significant RD is to
consider heart-kidney transplantation.
LVADs are increasingly implanted in patients with end-
stage heart failure as a bridge to transplantation (BTT) or as
destination treatment (DT) and have dramatically improved
both survival and morbidity (10,11). The newer axial-flow and
centrifugal-flow devices have the advantage of better durability
and smaller size and, therefore, have largely replaced older
pulsatile devices for both BTT and DT. Therefore, many
patients with heart failure with RD are considered for LVAD
implantation. However, whether LVAD implantation im-
proves or worsens renal function is unclear and has not been
specifically addressed by the major multicenter LVAD trials
(12–14).
The presence of pre-existing RD increases the risk after
general cardiac surgery (15) as well as after LVAD implan-
tation (16). Renal function may also deteriorate acutely after
cardiac surgery, and post-surgical acute RD has been iden-
tified in up to 45% of LVAD recipients. Surgical risk factors
including prolonged bypass time, increased intra-operative
blood loss, post-operative need for venovenous hemodialy-
sis, and reoperation were identified as negative predictors of
poor outcomes (17,18). Acute renal failure (ARF) after
LVAD implantation has been identified as a negative
predictor of outcomes (10,18,19). Another consideration
is whether the presence of a low pulsatility circulation, a
result of a continuous-flow device, might cause chronic
deterioration of renal function. Therefore, severe RD
(need for hemodialysis or serum creatinine 2.5 to 3
mg/dl deemed irreversible) is considered a significant
comorbidity and a relative contraindication for LVAD
implantation (20,21).
However, it is also possible that improved cardiac output
and hemodynamic status with reduction in venous pressure
may improve renal function. A recent study demonstrated
that 65.3% of patients with RD (GFR 60 ml/min/1.73 m2)
ctually had improved renal function by 1 month after
VAD implantation, to GFR 60 ml/min/1.73 m2. This
improvement was associated with improved survival. The
absence of diabetes was the only significant predictor
identified for renal recovery (16).
Therefore, the aim of this study was to evaluate the effects
of LVAD support on renal function in our cohort of BTT
and DT patients implanted with continuous-flow Heart-
Mate II devices (Thoratec Corporation, Pleasanton, Cali-
fornia) and to identify pre-operative predictors for improved
renal function within this population.
Methods
Patients. A retrospective analysis of data was performed for
our single-center experience of LVAD implantation for 103
patients from February 2007 to June 2010. Only HeartMate II
continuous-flow devices were followed (n  83, 80% of
adult LVAD implantations), and both BTT and DT qpatients were included. Twenty
patients with other devices (8 with
Jarvik 2000 [Jarvik Heart, Inc.,
New York, New York], 6 with
VentrAssist [Ventracor, Sydney,
Australia] and 6 with HeartMate
XVE [Thoratec Corporation]
were excluded from analysis. This
study was approved by the institu-
tional review board.
Renal function. Renal function
was assessed by calculating the
GFR using the abbreviated
Modification of Diet in Renal
Disease equation: GFR 186
(serum creatinine [mg/dl])1.154
 (age [years])0.203 0.742 (if female) (22). The equation
as previously been validated in the general, heart failure,
23,24) and heart transplantation (8) populations. Previous
tudies in the LVAD population have used both the
ockcroft-Gault (25) and the Modification of Diet in Renal
isease equations (16).
Renal function was assessed at admission for LVAD
mplantation (determined as baseline renal function), the
orning before LVAD implantation, and 1 month (range
4 to 46 days), 3 months (range 56 to 120 days), and 6
onths (range 150 to 240 days) after implantation during
outine follow-up visits. Stages of RD were determined
ccording to calculated GFR in accordance with established
uidelines. A GFR cutoff of 60 ml/min/1.73 m2 was used
to differentiate mild or normal renal function from more
severe RD (26). Data were considered missing if a patient
died or underwent transplantation (for GFR after death
date or transplantation date) and if no creatinine measure-
ment was available. Patients requiring hemodialysis were
considered in stage 5 (GFR 15 ml/min/1.73 m2). Because
the actual GFRs in these patients were undetermined, they
were considered missing for analysis requiring numerical
GFR measurement.
Predictors of RD improvement. Possible pre-operative
predictors affecting renal function after LVAD implantation
for patients with available GFRs at 1 month (n  72) were
derived from patient files and electronic data. Special
attention was given to patients with baseline GFRs 60
ml/min/1.73 m2 for whom GFRs were available at 1 month
n  44), because there is often uncertainty regarding the
ecoverability of renal function in these patients going into
VAD implantation. Therefore, it would be helpful to
now which factors predict whether renal function is likely
o recover.
tatistical analysis. Data were collected into a JMP file
nd analyzed using SAS version 9.2 (SAS Institute Inc.,
ary, North Carolina) for association with renal function
ndependently by a coauthor of this report (Z.L.). Descrip-
ive statistics for categorical variables are reported as fre-
Abbreviations
and Acronyms
ARF  acute renal failure
BTT  bridge to
transplantation
CI  confidence interval
DT  destination treatment
GFR  glomerular filtration
rate
IABP  intra-aortic balloon
pump
LVAD  left ventricular
assist device
RD  renal dysfunctionuencies and percentages, while continuous variables are
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hange of GFR from 1 time point to another was tested
sing paired t tests or Wilcoxon signed rank tests. The
onferroni method was used to assess the significance of
ultiple comparisons. Linear regression models were used
o find the univariate and multivariate predictors of change
n GFR at 1 month. GFR was evaluated as a continuous
ariable, as previously described (27). The multivariate
odel considered pre-operative univariately significant vari-
bles (p  0.05), excluding variables with more than 20%
issing values. We used model selection using the stepwise
ackward and forward selection. All statistical tests were
-sided, with the alpha level set at 0.05 for statistical
ignificance.
esults
atient characteristics. Baseline characteristics for the 83
VAD patients are shown in Table 1. The mean age was 63 
12 years, and the majority of patients were men (82%). The
majority of LVADs (70%) were implanted as DT, and
about half of the patients had ischemic etiology. The main
reason for DT in these patients was older age (median 70 vs.
55 years for patients bridged to transplantation, p 0.0001)
as well as the presence of other comorbidities. About
one-half of the patients had chronic RD. Table 1 also shows
the baseline characteristics for the subset of 54 LVAD
patients with GFRs on admission 60 ml/min/1.73 m2 in
whom predictors of improvement in renal function were
subsequently evaluated. This cohort had a mean admission
GFR of 40  12 ml/min/1.73 m2. Compared with patients
ith preserved renal function (GFR 60 ml/min/1.73 m2),
hose with low baseline GFRs were significantly older, with
ore chronic kidney disease and longer pre-operative hos-
ital stays. These patients also had more right ventricular
ysfunction and higher wedge pressures.
enal function after LVAD implantation. GFR over the
ollow-up time period is shown in Figure 1A. GFR mea-
urements at 1 month were available for 72 patients (87%)
nd at 6 months were available for 57 patients (69%). At 6
onths, 12 patients had died, 6 patients had undergone
ransplantation, 5 patients had no follow-up creatinine
easurements, and 3 patients were alive on chronic dialysis.
verall GFR significantly improved 1 month after LVAD im-
lantation (from 53.2  21.4 to 87.4  27.9 ml/min/1.73 m2,
 0.0001). Thereafter, GFR partially declined at 3
months in 41 of 66 patients with GFR estimates at both
time points (77.6  22.8 ml/min/1.73 m2, p  0.0001,
ompared to 1 month). Between 3 and 6 months, GFR
urther declined in 36 of 55 patients with available GFR
stimates (71.2  21.0 ml/min/1.73 m2, p  0.0032,
ompared to 3 months). Only 6 patients had continuous
FR improvements without any decline over the study
eriod (67 had some decline or no recovery of RD, and data
ere missing for 10 patients). Overall, GFR remainedignificantly higher at 6 months compared to pre-operativeFR (p  0.0001). Figure 1B shows the changes in GFR
over time for the subsets of patients with pre-operative RD
(GFR 60 ml/min/1.73 m2) and preserved renal function
(GFR 60 ml/min/1.73 m2). Overall, both subsets fol-
owed the same pattern of change in GFR as the entire
ohort. The subset with pre-operative RD had a significant
ncrease at 1 month (p  0.0001), a partial decline (1 to 3
onths, p  0.0059; 3 to 6 months, p  0.0258), and
verall improvement over 6 months (p  0.0001). The
istribution of the stages of RD before and during follow-up
fter LVAD implantation is illustrated in Figure 2A. Consistent
ith the findings in Figure 1, an improved stage distribution
as noted after LVAD implantation. Similar trends were
oted for the large subset of patients in stage 3 before
mplantation, as illustrated in Figure 2B. Indeed, for pa-
ients with available renal staging at 1 month, 57 patients
72%) improved their RD stages or remained at stage 1.
ourteen patients (18%) remained in their pre-operative
enal stages (10 in stage 2, 4 in stage 3), and 8 (10%)
eteriorated (2 from stage 4 to 5, 5 from stage 3 to 5, and
from stage 2 to 3).
enal failure after LVAD implantation. Eight patients
10%) developed ARF after LVAD implantation necessi-
ating acute hemodialysis. Of these, 2 died in the early
ost-operative period, and 2 recovered renal function. Four
atients (5%) continued with chronic hemodialysis. The
linical characteristics and post-operative courses of these
atients are summarized in Tables 2 to 4. Predisposing
omorbidities included severe RD necessitating acute dial-
sis before transplantation (Patients #1, #5, and #7), prior
enal transplantation with severe RD for Fabry disease
Patient #2), multiple comorbidities (Patients #3 and #6),
nd insulin-dependent diabetes mellitus (Patients #4 and
8). Most patients (except Patient #8) had low GFRs before
VAD implantation. Patient #3 underwent emergent im-
lantation for previous device (HeartMate XVE) failure. All
atients had significant post-operative complications, in-
luding right ventricular dysfunction, infections, bleeding,
nd need for prolonged inotropic support. Renal function recov-
red in 2 patients. Four patients (Patients #2, #5, #6, and #8)
ied during the initial hospital stay after prolonged compli-
ated courses. The 2 other patients survived longer (1.5 and
.5 years) and died of nonrenal causes.
redictors of improved GFR 1 month after LVAD
mplantation. We used a univariate model for predicting
n increase in GFR (as a continuous variable) for the 72
atients with available GFR measurements at 1 month.
ignificant positive predictors associated with GFR im-
rovement were the use of an intra-aortic balloon pump
IABP) before surgery (slope  17, p  0.003), higher
bilirubin (slope  12.1, p  0.002) alanine transaminase
(slope  0.03, p  0.041), Lietz-Miller score (slope  1.5,
p  0.003), and higher right atrial pressure (slope  0.97,
p  0.048). An increase in GFR with optimal medical
treatment before surgery was associated with further improve-
ment 1 month after surgery (slope 0.6 per ml/min/1.73 m2,
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December 27, 2011/January 3, 2012:26–36 Renal Function After LVAD ImplantationPatient CharacteristicsTable 1 Patient Characteristics
Characteristic
All Patients
(n  83)
GFR <60 ml/min/1.73 m2
(n  54)
GFR >60 ml/min/1.73 m2
(n  29) p Value
Demographic
Age (yrs) 63.0 12.3 65.9 8.8 57.7 15.8 0.020
Men 68/83 (81%) 41/54 (76%) 27/29 (93%) 0.053
Hypertension 31/83 (37%) 20/54 (37%) 11/29 (38%) 0.936
Diabetes 24/83 (29%) 19/54 (35%) 5/29 (17%) 0.086
Chronic kidney disease 45/83 (54%) 41/54 (76%) 4/29 (14%) 0.001
Ischemic etiology 46/83 (55%) 30/54 (56%) 16/29 (55%) 0.973
BTT 27/83 (32%) 15/54 (28%) 12/29 (41%) 0.207
Clinical
GFR (ml/min/1.73 m2) 53.2 21.4 40.5 12.3 76.8 12.7 0.001
GFR pre-operative 64.5 22.5 55.4 18.2 81.3 20.2 0.001
Admission to operation time (days) 9.4 9.3 (n  83) 10.8 10.2 (n  54) 6.8 6.6 (n  29) 0.039
BMI (kg/m2) 28.9 5.6 28.8 5.8 29.2 5.3 0.782
NYHA class IV 50/81 (62%) 31/52 (60%) 19/29 (66%) 0.577
Prior sternotomy 42/83 (51%) 28/54 (52%) 14/29 (48%) 0.756
Atrial fibrillation 14/83 (17%) 8/54 (15%) 16/29(21%) 0.500
Kidney length (cm)
Left 11.7 1.2 11.5 1.2 11.9 1.3 0.287
Right 11.5 1.1 11.5 1.1 11.5 1.3 0.868
Preoperative IABP use 28/83 (37%) 20/54 (37%) 8/29 (28%) 0.385
Need for inotropes 59/83 (71%) 41/54 (76%) 18/29 (62%) 0.184
ACE inhibitors or ARBs 54/78 (69%) 34/51 (67%) 20/29 (69%) 0.585
Spironolactone 43/81 (53%) 29/53 (55%) 14/28 (50%) 0.686
Beta-blockers 68/81 (84%) 44/53 (83%) 24/28 (86%) 0.753
Loop diuretic agents 69/75(92%) 44/48 (92%) 25/27 (93%) 0.887
Digoxin 43/75 (57%) 28/48 (58%) 15/27 (56%) 0.815
Urine protein (mg/dl) 7 (4–23) (n  71) 7 (4–30) (n  45) 7 (4–18) (n  26) 0.756
Hemoglobin (g/dl) 11.9 1.9 11.7 2.0 12.4 1.7 0.100
Platelet count (1,000) 175.6 70.0 167.1 61.0 191.0 83.0 0.286
Bilirubin (mg/dl) 1.2 0.7 1.2 0.7 1.4 0.8 0.171
NT-proBNP (pg/ml) 6,004 5,812 (n  47) 7,521 6,578 (n  29) 3,559 3,143 (n  18) 0.014
Albumin (g/dl) 3.8 0.6 3.7 0.5 3.8 0.7 0.486
BUN (mg/dl) 31.6 16.8 35.2 17.6 25.0 12.9 0.005
Creatinine (mg/dl) 1.6 0.7 1.9 0.7 1.1 0.2 0.001
Lietz-Miller score 9.6 6.0 10.3 6.0 8.6 5.7 0.156
VO2max (% predicted) 39.4 11.3 (n  42) 39.6 8.5 (n  25) 39.1 11.8 (n  17) 0.885
Pre-operative echocardiography
Left ventricular diastolic diameter (mm) 67.2 9.5 (n  82) 67.9 9.4 (n  53) 66.0 9.6 0.379
Ejection fraction (%) 19.8 8.6 (n  83) 19.2 6.3 (n  54) 20.9 11.7 (n  29) 0.908
RIMP 0.6 0.2 (n  75) 0.6 0.2 (n  48) 0.5 0.3 (n  27) 0.440
RV dysfunction more than moderate 54/81 (67%) 40/52 (77%) 14/29 (48%) 0.009
Pre-operative catheterization
Mean right atrial pressure (mm Hg) 15.4 6.7 (n  80) 15.9 6.5 (n  52) 14.5 7.2 (n  28) 0.388
Mean pulmonary pressure (mm Hg) 36.1 9.3 (n  80) 36.8 9.0 (n  52) 34.8 9.9 (n  28) 0.350
RVSWI (g/m2/beat) 7.1 3.9 (n  74) 7.0 3.7 (n  49) 7.3 4.3 (n  27) 0.776
Mean wedge pressure (mm Hg) 23.5 6.9 (n  77) 24.6 6.6 (n  50) 21.4 7.1 (n  27) 0.049
Cardiac index (l/min/m2) 1.9 0.5 (n  78) 1.9 0.6 (n  50) 2.1 0.5 (n  28) 0.073
Operation
Bypass time (min) 103.6 33.7 (n  82) 105.6 32.9 (n  54) 99.8 35.5 (n  28) 0.350
Duration of hospitalization (days) 21.4 13.3 (n  75) 22.2 14.2 (n  47) 20.1 11.8 (n  28) 0.576
Values are mean SD or n/N (%). The table depicts baseline characteristics of 83 patients implanted with HeartMate II LVADs and of the subgroups of patients with baseline GFRs60 or60 ml/min/1.73 m2.
ll comparisons are between patients with baseline GFR60 and 60 ml/min/1.73 m2.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass index; BTT  bridge to transplantation; BUN  blood urea nitrogen; GFR  glomerular filtration rate; IABP intra-aortic balloon pump; LVAD left ventricular assist device; NT-proBNP N-terminal pro–B-type natriuretic peptide; NYHA New York Heart Association; RIMP right index of myocardial performance; RV
right ventricular; RVSWI  right ventricular stroke work index; VO2max  peak oxygen uptake.
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Figure 1 GFR Change After LVAD Implantation With Time
Glomerular filtration rate (GFR) is shown (A) for the whole group and (B) for the subgroup with admission GFRs 60 ml/min/1.73 m2 (full line, upper error bars) and
the subgroup with admission GFRs 60 ml/min/1.73 m2 (dashed line, lower error bars). GFR was calculated using the Modification of Diet in Renal Disease equation
according to creatinine levels at admission for left ventricular assist device (LVAD) surgery, on the day of operation, and at the 1-, 3-, and 6-month scheduled visits for
available patients (see text). Change of GFR between 2 time points was tested using paired t tests by using patients whose GFR data were available at both time points
compared. *p  0.007 represent significant differences between measurements by Bonferroni correction for multiple comparisons.
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Stage 5 (<15) 1 1 7 8 3 4 3 4
missing 0 0 4 5 14 17 23 28
Renal dysfunction stage distribution-subset with stage 3 at baseline
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Stage 3 (30-60) 42 100 4 10 7 17 8 19
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Figure 2 RD Stage Distribution Before and After LVAD Implantation
The figures and corresponding tables illustrate the distribution of glomerular filtration rate (GFR) by the various stages of renal dysfunction (RD) before left ventricular
assist device (LVAD) implantation (baseline) and during follow-up (1, 3, and 6 months). Data for all patients (A) and for those with stage 3 RD (B) are shown. Missing
data include patients in whom creatinine was not measured as well as those who died or underwent transplantation during follow-up.
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00-rpm increase, p 0.01) was also associated with improved
FR. Negative predictors were having at least 1 kidney smaller
han 10 cm on ultrasound (slope  23.7, p  0.01) and
reatment with an angiotensin pathway inhibitor (angiotensin-
onverting enzyme inhibitor or angiotensin receptor blocker)
efore surgery (slope  15.7, p  0.006). The multivariate
odel suggested that having at least 1 kidney smaller than 10 cm
slope21; 95% confidence interval [CI]:37.7 to4.6; p
.012), use of an IABP (slope 11.8; 95% CI: 0.8 to 22.8; p
.035) and Lietz-Miller score (slope 1.2 per unit increase; 95%
I: 0.25 to 2.11; p  0.013) were independent predictors.
To determine the predictors of improved GFR after
VAD implantation in patients with significant pre-
perative RD, we focused our analysis on patients with
aseline GFRs 60 ml/min/1.73 m2 (stages 3 to 5). For
his subset of 54 patients, data were available at 1 month for
4 patients, as 3 died and 7 were on hemodialysis. Overall,
FR improved from 40  12 to 80  27 ml/min/1.73 m2,
as shown in Figure 1B. For patients with available staging,
34 (67%) had improved GFRs (to 60 ml/min/1.73 m2) at
1 month, and 17 (33%) did not. A univariate model for
prediction of increase in GFR (as a continuous variable) is
shown in Table 5. Positive predictors associated with GFR
Demographic Characteristics of Patients Needing Chronic DialysisTable 2 Demographic Characteristics of Patients Needing Chro
Patient #
Age
(yrs) Sex Medical History
1 59 Female HTN, CKD (CVVHD), severe lung disease
2 62 Male CKD s/p transplantation, (Fabry), lung disease, s/p
3 74 Male HTN, CKD, IHD
4 61 Male HTN, DM
5 67 Male Complex congenital heart disease, recurrent VT, CK
6 73 Male s/p B-cell lymphoma, s/p CABG, DM, CKD, on conti
milrinone infusion (4 yrs)
7 45 Female Recent mitral repair  Maze procedure, shock, acu
failure (CVVHD)
8 48 Male Radiation cardiomyopathy, s/p NHL, DM, CVVHD
Demographic characteristics of patients who succumbed to chronic need for hemodialysis are sum
by ultrasound before implantation.
AF  atrial fibrillation; CABG  coronary artery bypass grafting; CKD  chronic kidney disease; C
hypertension; IHD  ischemic heart disease; LM  Lietz-Miller; NA  not available; NHL  non-Hod
abbreviations as in Table 1.
Pre-Operative Clinical Characteristics of Patients Needing ChronicTable 3 Pre-Operative Clinical Characteristics of Patients Need
Patient #
GFR
(ml/min/1.73 m2)
Pre-Operative
GFR Improvement
Hb
(mg%)
Albumin
(g%)
1 24 24 9.2 3.1
2 20 10 11.2 2.8
3 39 17 10.2 3.3
4 38 0 9.8 3.8
5 32 13 11.1 3.3
6 40 18 12.4 3.5
7 41 43 9.8 3.3
8 76 0 10.9 NA
Pre-operative clinical characteristics of patients who succumbed to chronic need for hemodialysi
parameters (TR and MR), and catheterization parameters (RVSWI, RAP, and wedge pressure).
Hb  hemoglobin; MR  mitral regurgitation; RAP  right atrial pressure; RVSWI  right ventricular simprovement included atrial fibrillation at baseline, higher
bilirubin and Lietz-Miller score, an increase in GFR (from 40
 12 to 55  18 ml/min/1.73 m2) with optimal medical
reatment before surgery, the use of an IABP before surgery,
igher LVAD pulsatility index at discharge, and pump speed
etting in the higher range (9,200 rpm). Negative predictors
ncluded older age, having at least 1 kidney smaller than 10 cm (on
ltrasound before operation), and treatment with an angiotensin
athway inhibitor (angiotensin-converting enzyme inhibitor or
ngiotensin receptor blocker) before surgery. The multivariate
odel suggested that the increase in GFR with optimal treatment
efore surgery (slope  0.5 U per unit increase; 95% CI: 0.2 to
.8; p  0.0028), atrial fibrillation at baseline (slope  27; 95%
I: 7.7 to 46.4; p  0.0062), and the use of an IABP (slope 
3.9; 95% CI: 1.8 to 26.1; p  0.0244) were independent
redictors.
iscussion
he issue of RD after LVAD implantation is important for
number of reasons. First, the possible need for chronic
ialysis after LVAD implantation may influence the deci-
ion about whether to proceed. Second, the question of
eversibility of RD is important regarding the need for
LVAD Implantationialysis After LVAD Implantation
Transplantation
Candidacy
Small Kidney
(<10 cm)
NYHA Functional
Class Rhythm
LM
Score
BTT Yes IV AF 13
BTT NA IIIb AF 21
DT No IIIb AF 22
DT No IV Sinus 6
HD) BTT No IV Sinus 24
DT NA IV AF 4
l BTT No IV AF 20
BTT No III Paced 10
d, including the LM score for post-LVAD prognosis and the dimension of the kidney as determined
continuous venovenous hemodialysis; DM  diabetes mellitus; DT  destination therapy; HTN 
phoma; s/p  status post; TVR  tricuspid valve replacement; VT  ventricular tachycardia; other
sis After LVAD Implantationhronic Dialysis After LVAD Implantation
TR MR RVSWI
RAP
(mm Hg)
Wedge Pressure
(mm Hg)
Severe Moderate to severe 5 25 21
Severe Moderate 1.3 12 22
Moderate None 11.7 11 19
Moderate None 1.9 34 32
None None NA NA NA
Moderate Mild 5.1 23 27
Severe None 2.4 20 25
Moderate Mild 1.4 35 35
mmarized, including laboratory results (GFR, albumin, and Hb), use of IABP, echocardiographicAfternic D
TVR
D (CVV
nuous
te rena
marize
VVHD Dialying C
IABP
No
Yes
No
Yes
Yes
Yes
Yes
Yes
s are sutroke work index; TR  tricuspid regurgitation; other abbreviations as in Tables 1 and 2.
1mmari
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plantation in BTT candidates. Therefore, it would be
helpful to be able to predict whether renal function is likely
to improve or worsen after axial-flow LVAD implantation.
Our study cohort reflects the current trends in LVAD
implantation as recently documented in the third Inter-
agency Registry for Mechanically Assisted Circulatory Sup-
port report, with increasing proportions of DT implanta-
tions and continuous-flow devices (28). In some respects,
however, our cohort may represent a more chronically ill
population, as it includes older patients and fewer BTT
candidates (30% vs. 40%). Given that continuous-flow
pumps currently account for more than 98% of adult primary
LVAD implantations in the United States, our choice of pump is
in keeping with national trends. The HeartMate II pump is
currently the only device approved by the U.S. Food and
Drug Administration for the rapidly expanding DT popu-
lation, and therefore we felt that restricting our analysis to
HeartMate II implantations was reasonable.
The major finding of this study is the dramatic improve-
ment in renal function with LVAD support. The small but
significant improvement in renal function before operative
intervention can be attributed to improved hemodynamic
management and consequent better renal perfusion. How-
ever, despite this initial improvement, we observed contin-
ued improvement after LVAD implantation, suggesting
that medical and IABP intervention was not sufficient to
restore optimal renal perfusion. Previous studies have fo-
cused on the occurrence of ARF early after LVAD implan-
tation, with incidence as high as 32% or 45% (17,18) and
16% in the Thoratec HeartMate II LVAS (Left Ventricular
Assist System) for Destination Therapy study (14). In the
present study, the development of ARF was less frequent
(10%). We agree with previous reports that the development
of ARF may result from an unfavorable early post-operative
course and early hemodynamic instability (17). The majority
of patients in our cohort actually had improved renal
function with LVAD support. GFR significantly increased
Post-Operative Characteristics of Patients Needing Chronic DialysiTable 4 Post-Operative Characteristics of Patients Needing Ch
Patient # Complications
Duratio
Su
1 GI bleeding, pneumonia, prolonged intubation, RV
dysfunction, MR (moderate), continued need for dialysis
2 Early RV failure, sepsis, prolonged intubation, VT
3 Early HeartMate XVE failure, emergent HeartMate II
implantation, mediastinitis, RV dysfunction
4 Early RV failure, prolonged intubation, sepsis, RV dysfunction
5 Early RV failure, prolonged intubation, recurrent VT
encephalopathy, sepsis, ileus, hyperbilirubinemia
6 Delayed chest closure, prolonged intubation,
encephalopathy, biliary sepsis
7 Early RV failure, delayed chest closure, prolonged ventilation
8 Chest reopening for severe bleeding, shock
Post-operative characteristics of patients who succumbed to chronic need for hemodialysis are su
GI  gastrointestinal; other abbreviations as in Tables 1 to 3.from 53.2  21.4 ml/min/1.73 m2 at baseline to 87.4 27.9 ml/min/1.73 m2 at 1 month and to 71.2  21.0
ml/min/1.73 m2 at 6 months. Among patients with pre-
operative RD, 34 (67%) had improved GFRs to above 60
ml/min/1.73 m2 at 1 month. These results are in agreement
with previous reports for the pulsatile pump (25) as well as
continuous-flow implants in the BTT population (16). Our
findings therefore validate previous observations showing
improved renal function in the current population of pa-
tients with LVAD implants with continuous-flow pumps.
The reversibility of RD in the cardiorenal syndrome is a
major issue in patients being considered for heart transplan-
tation. RD is the most common modifiable contraindication
to heart transplantation in LVAD patients (28). Indeed, in
the face of progressive RD, heart transplantation may be
deferred, or heart-kidney instead of heart transplantation
alone may be considered. In a recent analysis, a cutoff GFR
33 ml/min/1.73 m2 was suggested for this strategy, with
-year results better than for heart transplantation alone (29).
Another report identified less post-transplantation RD in a small
group of patients supported with LVADs as BTT compared
with inotropic support (30). Our findings suggest that
LVAD support before heart transplantation may help differ-
entiate between reversible and nonreversible kidney disease.
Another interesting observation is that although GFR
generally improves with LVAD support, a gradual partial
but significant decline was observed at 3 and at 6 months
compared with 1 month after the operation. These findings
are also consistent with previous reports (16), and 1 expla-
nation may be that the very low muscle mass after surgery
may decrease creatinine levels and result in overestimation
of GFR at 1 month. In our analysis, low pre-operative
albumin as a marker for cachexia showed a trend for
predicting higher GFR (lower creatinine). The progressive
expected increase in muscle mass at 3 and 6 months may
correct for that bias. Resuming treatment with angiotensin
pathway inhibitors could influence the late decline in
renal function. However, this did not come up as a
significant predictor in our analysis (data not shown).
r LVAD ImplantationDialysis After LVAD Implantation
otropic
(h) Hospital Stay Late Outcome
65 days Died (sepsis) 2.5 yrs after implantation
Death 76 days In-hospital death
28 days Withdrew support 1.5 yrs after implantation
52 days Recovered renal function 6 months after implantation
Death 37 days In-hospital death
Death 44 days In-hospital death
61 days Recovered renal function 45 days after implantation
Death 7 days In-hospital death
zed.s Afteronic
n of In
pport
160
1,032
446
504
1,488
1,056
1,320
168Another explanation is that lack of pulsatile flow may
[B
e
d
p
a
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studies comparing non-pulsatile-flow and pulsatile-flow
LVADs were not supportive of this suggestion (31). In
the present study, higher pump speed settings were
Univariate Linear RegressionModel Pr dicting Increase i GFR 1 MonthAfter LVAD Implantation for PatientsWith Admissio GFRs <60 ml/mi /1.73 m2
Table 5
Univariate Linear Regression
Model Predicting Increase in GFR 1 Month
After LVAD Implantation for Patients
With Admission GFRs <60 ml/min/1.73 m2
n
Parameter
Estimate 95% CI p Value
General
Age 44 0.8 1.6 to 0.0 0.049
Male* 44 4.2 12.8 to 21.1 0.630
HTN* 44 0.4 15.1 to 14.2 0.954
DM* 44 0.6 15.4 to 14.2 0.936
CKD* 44 11.5 27.1 to 4.1 0.151
BTT* 44 9.1 6.6 to 24.9 0.256
Ischemic etiology* 44 4.5 10.1 to 19.0 0.549
Weight 44 0.2 0.6 to 0.2 0.300
Body surface area 44 18.1 46.0 to 9.8 0.204
Diastolic blood pressure 44 0.2 1.2 to 0.5 0.474
Systolic blood pressure 44 0.2 0.7 to 0.3 0.413
Heart rate 44 0.0 0.5 to 0.5 0.974
AF* 44 31.8 8.8 to 54.7 0.007
NYHA class IV* 44 10.0 4.1 to 24.1 0.163
Small kidney (10 cm)* 40 24.7 46.0 to3.5 0.023
VO2max (% predicted) 20 0.6 0.5 to 1.7 0.294
GFR increase, admission
to pre-operative
44 0.6 0.3 to 0.9 0.001
Scores
Lietz-Miller score 44 1.6 0.2 to 2.9 0.019
Matthews score 44 2.4 0.4 to 5.2 0.091
Kormos score 41 3.5 1.2 to 8.2 0.149
Treatment before surgery
IABP used* 44 20.5 6.7 to 34.2 0.004
Inotropes* 43 2.8 20.1 to 14.4 0.745
ACE inhibitors or ARBs* 44 15.5 29.4 to1.6 0.029
Beta-blockers* 44 5.4 23.9 to 13.0 0.562
Aldosterone inhibitors* 44 5.6 8.5 to 19.8 0.435
Diuretic agents* 40 14.4 39.4 to 10.6 0.258
Amiodarone* 40 6.9 22.8 to 8.9 0.390
ICD/CRT* 40 4.7 20.0 to 10.7 0.550
Digoxin* 40 8.1 23.6 to 7.4 0.307
Statins* 40 7.0 9.5 to 23.5 0.404
Laboratory results
Urine protein 36 0.1 0.1 to 0.3 0.466
GFR on admission 44 0.1 0.7 to 0.4 0.626
Hemoglobin 44 0.5 4.0 to 3.0 0.779
Bilirubin 44 14.6 5.6 to 23.7 0.002
AST 44 0.0 0.0 to 0.1 0.193
ALT 41 0.0 0.0 to 0.0 0.157
LDH 37 0.0 0.0 to 0.0 0.210
BNP 25 0.0 0.0 to 0.0 0.768
Platelets 44 0.0 0.1 to 0.1 0.943
BUN 44 0.0 0.4 to 0.4 0.975
Albumin 43 13.2 28.1 to 1.7 0.082
Continued in next columnassociated with improved 1-month renal function. Incontrast, a higher pump pulsatility index was also asso-
ciated with improved GFR. Further study is needed to
evaluate for long-term effects of axial-flow LVAD sup-
port on renal function as well as ways to facilitate optimal
cardiac output, venous pressures, and arterial pulsatility
with a continuous-flow pump.
One of our major goals was to ascertain pre-operative
predictors for improved renal function in patients with
LVAD support. We focused our analysis on patients with
pre-operative RD (grade 3 and below) who had the poten-
tial for improved renal function. Interestingly, our univariate
analysis identified high bilirubin, atrial fibrillation, and
partial reversibility of RD with optimal treatment before
ContinuedTable 5 Continued
n
Parameter
Estimate 95% CI p Value
Echocardiography
RIMP 39 3.2 38.5 to 32.2 0.861
TR time (corrected) 42 0.1 0.2 to 0.0 0.174
LVEDD 44 0.4 1.3 to 0.4 0.320
Mitral E-wave 39 5.3 17.7 to 28.2 0.653
LA volume index 43 0.1 0.5 to 0.4 0.794
EF 44 0.2 1.4 to 0.9 0.684
LV mass 34 0.0 0.1 to 0.0 0.130
TR (more than moderate) 44 0.5 14.8 to 13.7 0.941
AR (more than moderate) 44 7.1 35.3 to 21.1 0.623
MR (more than moderate) 44 3.5 10.9 to 17.8 0.633
Catheterization
Stroke volume index 42 0.2 0.9 to 0.6 0.682
RVSWI 42 0.7 2.8 to 1.5 0.537
Cardiac index 42 2.7 16.7 to 11.3 0.704
SVR 31 0.6 1.5 to 0.4 0.242
PVR 42 0.4 2.7 to 2.0 0.757
RA pressure (mean) 43 0.7 0.5 to 2.0 0.262
Wedge pressure (mean) 41 0.4 1.5 to 0.7 0.452
PA pressure (mean) 43 0.1 0.7 to 0.9 0.821
Surgery and pump settings
Bypass time 44 0.0 0.2 to 0.2 0.928
Discharge pump flow 43 0.5 9.5 to 10.5 0.920
Discharge LVAD pulsatility index 42 12.6 0.5 to 24.8 0.042
Discharge pump speed (200 rpm) 42 7.4 1.8 to 13.0 0.009
Discharge pump speed9,200 rmp* 42 22.0 6.9 to 37.2 0.004
The table shows the results of a univariate linear regression analysis for prediction of increase in GFR
1 month after LVAD implantation. GFR was evaluated as a continuous variable. We estimated the
associations of various pre-operative variables with increased GFR (operative time and LVAD settings
were also included). Estimates were calculated depicting the change in mean GFR associated with the
variable measured before and 1 month after operation. Estimates for continuous variables are for
change inmeanper unit increase in the evaluated variable. p values0.05were considered significant.
TR time was corrected for pulse; RIMP  (TR time  RV ejection time)/RV ejection time; RVSWI 
0.0136  (MPAP  RAP)  stroke volume index]; kidney size was assessed by pre-operative
abdominal ultrasound. Scores for prediction of outcomes (Lietz-Miller, Matthews, Kormos) were
calculated as previously published. *Categorical predictors were assessed using 1-way analysis of
variance.
ALT  alanine transaminase; AR  aortic regurgitation; AST  aspartate transaminase; BNP 
-type natriuretic peptide; CI confidence interval; CRT cardiac resynchronization therapy; EF
jection fraction; ICD  implantable cardioverter-defibrillator; LA  left atrial; LDH  lactate
ehydrogenase; LVEDD  left ventricular end-diastolic dimension; PA  pulmonary artery; PVR 
ulmonary vascular resistance; RA  right atrial; SVR  systemic vascular resistance. Other
bbreviations as in Tables 1 to 4.operation as well as the use of an IABP as positive predictors
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kidney size were negative predictors. We found the negative
association of angiotensin inhibitors surprising, although
previous reports of kidney dysfunction after heart transplan-
tation suggested similar results (8). The predictors that were
significant in the multivariate model were RD partial
reversibility, the use of an IABP, and atrial fibrillation.
Previous studies have identified only diabetes mellitus as a
significant predictor (16). Despite a similar proportion of
patients with diabetes in the present study, we did not find
this to be a significant predictor. Recently, a new nomen-
clature for the cardiorenal syndromes was developed, differ-
entiating between primarily cardiac or renal etiology (7).
The positive predictors found in our analysis (atrial fibril-
lation, high right atrial pressure) may represent stronger
cardiac-derived cardiorenal syndrome (type 2), while the
negative predictors (small kidney, older age) represent less
primary renal (type 4) cardiorenal syndrome.
The use of LVADs has improved our ability to understand
the physiology of complex multiple-organ syndromes involving
the heart, because they acutely improve cardiac output and
hemodynamic status. We observed that in our population of
patients with advanced heart failure, prompt assistance of left
ventricular function resulted in reversibility of established
cardiorenal syndrome. Therefore, our results suggest that
although long-standing renal hypoperfusion may cause RD,
irreversible pathological tissue damage is limited and restora-
tion of perfusion is likely to improve function.
Study limitations. Our study had the limitations of a
retrospective analysis. A further limitation was the declining
number of patients in whom renal function was evaluated
during follow-up (because of patient death, transplantation,
missing measurements, and renal deterioration leading to
hemodialysis). Therefore, the GFR estimates later in the
post-implantation course might be biased to healthier pa-
tients. We therefore examined GFR at various time points,
used paired analysis for trends in GFR, and selected the
1-month GFR (with less patient dropout) for our analysis of
predictors. Because of the limited data points, only 3
parameters could be fitted into the multivariate model. This
potentially could result in the underestimation of other potential
independent predictors beyond the ones evaluated. Baseline
comparison between the 72 patients with GFR results at 1
month and the 11 patients missing indicates that missing
patients were sicker (more chronic kidney disease, lower
GFRs on admission, lower hemoglobin, higher aspartate
transaminase, higher international normalized ratios). They
also had shorter tricuspid regurgitation times and smaller
left ventricles. Operations were longer, with more need for
blood products, and their hospital stays were longer as well.
Detailed investigation of the duration, course, and contrib-
uting factors of pre-operative RD was not available in our
analysis and might have added predictive variables to our
predictive model.Conclusions
In most patients with end-stage heart failure considered for
LVAD, renal dysfunction is reversible. Acute renal failure
after LVAD is less common than previously reported and is
associated with a complicated post-operative course. Pre-
diction of post-operative improvement in renal dysfunction
should take into account the likely contribution of renal
hypoperfusion and congestion, irreversible renal injury and
response to medical treatment pre-implant.
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